This article has Open Peer Review reports available.
Ascorbic acid ameliorates renal injury in a murine model of contrast-induced nephropathy
© The Author(s). 2017
Received: 14 June 2016
Accepted: 2 March 2017
Published: 24 March 2017
Contrast induced nephropathy (CIN) is the commonest cause of iatrogenic renal injury and its incidence has increased with the advent of complex endovascular procedures. Evidence suggests that ascorbic acid (AA) has a nephroprotective effect in percutaneous coronary interventions when contrast media are used. A variety of biomarkers (NGAL, NGAL:creatinine, mononuclear cell infiltration, apoptosis and RBP-4) in both the urine and kidney were assayed using a mouse model of CIN in order to determine whether AA can reduce the incidence and/or severity of renal injury.
Twenty-four BALB/c mice were divided into 4 groups. Three groups were exposed to high doses of contrast media (omnipaque) in a well-established model of CIN, and then treated with low or high dose AA or placebo (saline). CIN severity was determined by measurement of urinary neutrophil gelatinase-associated lipocalin (NGAL):creatinine at specific time intervals. Histological analysis was performed to determine the level of mononuclear inflammatory infiltration as well as immunohistochemistry to determine apoptosis in the glomeruli by staining for activated caspase-3 and DNA nicking (TUNEL assays). Reverse transcriptase PCR (rtPCR) of mRNA transcripts prepared from mRNA extracted from mouse kidneys was also performed for both lipocalin-2 (Lcn2) encoding NGAL and retinol binding protein-6 (RBP4) genes. NGAL protein expression was also confirmed by ELISA analysis of kidney lysates.
Urinary NGAL:creatinine ratio was significantly lower at 48 h with a 44% and 62% (204.3μg/mmol versus 533.6μg/mmol, p = 0.049) reduction in the low and high dose AA groups, respectively. The reduced urinary NGAL:creatinine ratio remained low throughout the time period assessed (up to 96 h) in the high dose AA group. In support of the urinary analysis ELISA analysis of NGAL in kidney lysates also showed a 57% reduction (12,576 ng/ml versus 29,393 ng/ml) reduction in the low dose AA group. Immunohistochemistry for apoptosis demonstrated decreased TUNEL and caspase-3 expression in both low and high dose AA groups.
Ascorbic acid reduced the frequency and severity of renal injury in this murine model of CIN. Further work is required to establish whether AA can reduce the incidence of CIN in humans undergoing endovascular procedures.
Contrast-induced nephropathy (CIN) is the commonest cause of iatrogenic renal injury and its incidence is increasing due to the rise in the number and complexity of endovascular interventions . This is increasingly apparent with prolonged endovascular aortic interventions such as fenestrated endovascular aortic aneurysm repair where high intra-arterial x-ray contrast media volumes may be administered. CIN is therefore a significant clinical problem, accounting for 10% of all hospital-acquired renal insufficiency , and is strongly associated with adverse clinical outcomes and prolonged hospital length of stay . The development of CIN is associated with an increase in both in-hospital and 1-year mortality, irrespective of whether dialysis is necessary . The quoted incidence of renal insufficiency following open and endovascular aneurysm repair (EVAR) varies widely [1, 5, 6], and it is clear that the cause of this damage is complex and may include aortic/stent-graft manipulation, blood loss and anaesthetic factors as well as CIN. In spite of these complications the patient benefit of less invasive EVAR (compared to conventional surgery) is, however, significant in that the risk of renal hypo perfusion secondary to hemodynamic instability and cross clamping is eliminated, surgical trauma is reduced, and ischemia-reperfusion injury is attenuated. However, EVAR still causes a significant systemic reaction, possibly through a combination of ischemia-reperfusion injury. Moreover, while the contemporary literature may suggest that EVAR protects the kidneys perioperatively, emerging data raise the possibility that long-term renal injury may be greater following EVAR than after an open operation .
Much attention has been paid to measures to reduce the incidence and severity of renal insufficiency associated with CIN. A recent meta-analysis  investigating multiple agents in this setting including N-acetylcysteine (NAC), theophylline, furosemide, dopamine, bicarbonate, iloprost and statins concluded that only NAC and theophylline had a demonstrable benefit compared with hydration alone, whereas furosemide had a detrimental effect upon renal function. Within the setting of vascular surgery the role of NAC is controversial [8–10] and not universally utilised. The role of AA in CIN associated with percutaneous cardiac interventions and radiographic imaging, likely due to its antioxidant properties, has been previously demonstrated to be beneficial in high-risk patients [10, 11] however the evidence for its routine use is again unclear [12, 13].
The mechanism of CIN is not well established but is thought to be related to renal vasoconstriction and increased osmotic load producing regional hypoxia, particularly in the renal medulla, which is susceptible to hypoxia. Post-ischaemic oxidative changes lead to an increase in production of free radical species, which in turn produce renal damage [14, 15]. Therefore AA as an anti-oxidant is thought to work in its role as a free radical scavenger.
Currently there is no data from either clinical or in vivo models assessing the potential of AA as a nephroprotective agent in patients undergoing endovascular aneurysm repair. The aim of this study was to investigate the role of AA in preventing CIN using an in vivo murine model. This was achieved using a variety of biomarkers including NGAL, RBP-4, apoptosis (TUNEL and Caspase 3) and karyolysis/inflammation (H&E staining) known or suspected to be associated with kidney damage. The biomarkers were measured using different assay formats (immunohistochemistry, ELISA, RT-PCR and histopathology) in order to determine if pre-treatment with AA has a potential therapeutic benefit in preventing CIN.
Charles River UK performed in vivo studies in which four groups of six BALB/c mice (weighing 6g each) were injected with nitric oxide synthase inhibitors (NG -nitro-L-arginine methyl ester, 10mg/kg) and an inhibitor of prostaglandin synthesis (indomethacin 10mg/kg) intraperitoneally before Omnipaque administration (isohexol, 350mg iodine/ml, 1.5–3g iodine/kg). This is an established model for generating reproducible renal failure following radiocontrast injection . Two groups were then given either low (0.056g/kg) or high dose AA (0.112g/kg) prior to contrast administration then after 12 and 24 h. The positive control group was given intravenous saline hydration 24 h post-administration of contrast media. The negative control group comprised no administration of contrast media and received intravenous saline hydration alone for the same time period. Urine was collected and pooled from each group before and after contrast injection, at 48 and 96 h then centrifuged and analysed for NGAL and creatinine. The NGAL: creatinine ratio was then calculated. At the end of the study kidneys from each mouse were explanted and frozen at -80°C.
Standard histological techniques were used to fix and embed one kidney, per mouse, in paraffin. Representative slices were stained with haematoxylin-eosin (HE) and scored for damage to the tubules. The parameters for scoring were karyolysis (scored in both the inner and outer cortex) and inflammation (as scored by the presence of mononuclear cells in both the cortex and medulla). Each parameter was scored from 0 to 4 with 0 representing no damage, 1 as mild, 2 as moderate, 3 as severe and 4 as very severe/extensive.
Immunohistochemistry and imaging
The explanted murine kidneys were frozen in liquid nitrogen and one kidney from each animal used for Caspase-3 and TUNEL (transferase mediated dUTP nick –end labelling). The tissue was cut to 10-μm sections on cryostat and thaw mounted on SuperFrost slides (VWR, West Sussex, UK). For both detection methods sections were fixed in 2% paraformaldehyde (PFA) in 1x phosphate buffered saline (PBS) for 10min and rehydrated in 1x PBS for 15min. For activated Caspase-3 staining only cell membranes were permeabilised in PBS containing 0.5% Tween-20 for 10min and washed 3x with 1x PBS + 0.05% Tween-20 for 5 min each. The sections were blocked for 1h in blocking solution containing 2% BSA and 5% goat serum in 1x PBS and washed 3x with 1x PBS for 5 min each. All incubation steps were performed at room temperature. Rabbit polyclonal anti-active Caspase-3 (p17 fragment) antibody (Abcam, Cambridge, UK) was diluted 1:100 in blocking solution and incubated with the sections overnight at 4°C. After 3 washes in 1x PBS Alexa Fluor 488-labeled goat anti-rabbit secondary antibody (Invitrogen. Paisley, UK) was applied at 1:100 dilution in blocking solution and incubated for 1h at room temperature in the dark. After 3 washes in 1xPBS/0.05% Tween20 the sections were mounted with Vectashield medium containing DAPI (Vector Laboratories, Peterborough, UK).
For TUNEL staining APO-BrdU™ TUNEL Assay Kit (Invitrogen, Paisley, UK) was used and protocol adapted for fluorescence microscopy. After fixation and rehydration as described above, sections were incubated in 70% ice-cold ethanol at -20°C for 30 min. Ethanol was removed and rinsed 3x with Wash Buffer. DNA-labelling solution was prepared as per manufacturer instructions and applied on sections overnight at 4°C. After washing with Rinse Buffer Alexa Fluor®488-labeled anti-BrdU mouse monoclonal antibody was applied as per manufacturer instructions and incubated 1h at room temperature in the dark. Sections were rinsed with PBS/0.05% Tween and stained with propidium iodide/RNase A staining buffer for 1 h at room temperature in the dark. After 3 washes in 1xPBS/0.05% Tween20 the sections were mounted with Vectashield medium containing DAPI (Vector Laboratories, Peterborough, UK).
Confocal fluorescent images were acquired using Zeiss LSM 510 Meta Confocal system (LSM software release 3.2) coupled to a Zeiss Axiovert 200 microscope. All images were acquired at room temperature.
mRNA analysis by quantitative real-time PCR
Quantitative real-time PCR (qRT-PCR) was conducted on the explanted mouse kidneys. Total RNA was extracted from frozen tissue samples using PARIS™ Kit (Life Technologies – Invitrogen, Paisley, UK). First strand cDNA synthesis was performed using QuantiTect Reverse Transcription Kit (Qiagen, Manchester, UK) from 100ng total RNA. All measurements were in duplicate and the relative expression levels of lipocalin-2 (Lcn-2) and retinol binding protein-4 (RBP-4) were each normalized hypoxanthine-guanine phosphoribosyltransferase (HPRT), glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and beta-2 microglobulin (B2M). qRT-PCR was performed on a BioRad CFX96 Real time PCR machine using QuantiTect SYBR Green PCR Master Mix (Qiagen, Manchester, UK) and validated primer pairs Quantitact Primer Assay (Qiagen, Manchester, UK) for all tested and housekeeping genes. The PCR efficiency for each set of primers was previously established by analysing serial dilutions of cDNA.
Biochemical analysis of NGAL
NGAL was measured using a two-site time resolved fluorescence DELFIA immunoassay (PerkinElmer Inc, MA, USA). Nunc Maxisorp plates (PerkinElmer Inc, MA, USA) were coated overnight with a monoclonal anti-NGAL antibody (R&D Systems, MN, USA). After coating, the plates were washed three times with DELFIA wash buffer and blocked with 300μl of 1% BSA in PBS. Urine samples were diluted 1 in 5 in DELFIA Multibuffer (PerkinElmer Inc, MA, USA) before analysis. Standards were prepared from recombinant murine NGAL (R&D Systems, MN, USA). 50μl standards, diluted urine or diluted QC samples were added to the plate in duplicate followed by 100μl DELFIA Multibuffer (PerkinElmer Inc, MA, USA). The plate was incubated at room temperature for 2 h on a plate shaker. The plate was then washed 4 times using an automated plate washer and a biotinylated polyclonal anti-NGAL detection antibody (R&D Systems, MN, USA) added to the wells. The plate was then incubated at room temperature for a further 2 h on a plate shaker. The plate was then washed 4 times using an automated plate washer and Europium labelled streptavidin (PerkinElmer Inc, MA, USA) added to the wells. The plate was incubated at room temperature for a further 40 min on a plate shaker. The plate was then washed 6 times using an automated plate washer and 200μl Enhancement solution (PerkinElmer Inc, MA, USA) added to the wells. The plate was incubated for 10 min on a plate shaker before time-resolved fluorescence readings were taken on a Victor 3 plate reader (PerkinElmer Inc, MA, USA). Results were calculated using the MultiCalc software package (PerkinElmer Inc, MA, USA). The assay range was 78.1 pg/ml to 5000 pg/ml. Creatinine was measured using a standard certified biochemistry assay (Department of Biochemistry, Cambridge University NHS Trust).
For NGAL analysis from explanted kidney lysates, individual kidneys were ground in liquid nitrogen and processed using a PARIS™ kit (Life Technologies – Invitrogen, Paisley, UK); half the sample was used for total protein analysis. Total protein was estimated using a Bradford assay (Thermo Scientific, Loughborough, UK) and each kidney sample was diluted to 20 μg protein/ml. NGAL concentration was determined using a Human Lipocalin-2/NGAL Quantikine ELISA Kit (R&D Systems, Abingdon, UK).
Statistical analysis was undertaken using GraphPad Prism v5 (GraphPad Software, La Jolla, CA). Binomial data were analysed using contingency table analysis and Fisher’s exact test used to calculate significance levels. Continuous data was analysed with students’ t-test. Significance was determined using 95% confidence (p < 0.05) in all cases.
Histopathology and immunohistochemistry
Histopathology (haematoxylin-eosin) scoring of explanted kidneys for mononuclear inflammatory cell infiltration from four groups at 400x magnification where the groups have been scored: 0 = no damage, 1 = mild, 2 = moderate, 3 = severe and 4 = very severe/extensive
Individual replicate mouse kidney
Group 1 – Low dose AA
medulla not present
Group 2 – High dose AA
medulla not present
Group 3 – Positive Control
very little medulla present
3+ cortex and neutrophils
1+ medulla and neutrophils
Group 4 – Negative Control
Biochemical analysis NGAL, Lcn-2 and RBP-4
Contrast induced nephropathy is a predominant cause of hospital acquired renal injury. There are an increasing number of both diagnostic investigations and therapeutic procedures performed using radio-contrast. Furthermore an ageing population, with a higher incidence of underlying renal impairment, make it imperative that greater attention is focused on the aetiology of CIN in order to formulate effective prophylactic and therapeutic strategies to reduce its incidence and associated morbidity and mortality . Contemporary evidence has highlighted significantly higher mortality rates in patients who suffer acute kidney injury after emergency aneurysm surgery at both 30-days and 12-months . Clearly there is a clinical need for therapeutic strategies aimed at prevention of CIN, and in this study we focused on investigating the potential of ascorbic acid in a murine model.
An established  murine model was selected that provides an effective model for CIN, and where a series of biomarkers could be measured to determine the nephroprotective effect of high dose AA on renal toxicity. Key biomarkers, from urine and explanted kidneys, selected for this study included NGAL (and the corresponding Lcn-2 mRNA transcript), NGAL:creatinine ratio (urine), apoptotic markers and kidney histology. Overall, the results demonstrated compelling evidence that in this murine model AA functions as a nephroprotective agent against CIN. These results add further weight to the evidence from the percutaneous cardiology setting [10, 12] that AA may be an agent, which could be transferred to the endovascular setting to counteract the influence of contrast media.
All the animals in this murine model had normal renal function prior to contrast administration. We know that in human studies patients with normal renal function are at the lowest risk of developing CIN. Further work in a murine model with pre-existing renal failure may demonstrate greater benefits of AA. The risk of developing CIN is greatest in patients with pre-existing renal impairment and diabetes. These patients are the most likely to benefit from the use of a nephroprotective agent. The risk of CIN in patients with normal renal function is likely to increase with the increasing complexity of endovascular interventions.
The low dose of AA trialled in this study was from a clinical perspective considered a ‘mega-dose’ in that the standard prophylactic daily dose quoted by the British National Formulary is 25–75mg (with a therapeutic dose of 250mg), therefore the high dose group should be regarded a high ‘mega-dose’. No deleterious effects either high or low dose AA were detected in this study, and both doses conferred some level of nephroprotection against CIN although in both the urinary NGAL:creatinine ratio and apoptosis assays, the high dose AA group appeared to be most resistant to CIN. Surprisingly, there have been no human clinical trials investigating the use of such a high dose AA in this setting, even used as a very short treatment. There have been advocates for mega-dosing of AA, particularly surrounding alternative medicine including the treatment of the common cold and in cancer therapy. The side effects from these doses (typically 2–4g daily) are nausea, vomiting, diarrhoea and renal calculi. However previous research has suggested that high dose AA is safe; Spargias et al.  used mega-doses of AA, administering 3g followed by 2g and 2g, and observed no negative side effects in their study group. Our study design calculated the low AA dose administered to the mice to be equivalent to the human dose utilised by Spargias et al . The dose of AA was based upon the standard human dose per kilogram body weight, with the high dose representing twice this dose, however still remaining within the previous documented megadosing regimens.
The most frequently quoted definition of CIN is an increase in serum creatinine of 25–50% from baseline, generally occurring within 24 h of contrast administration. With this in mind urine collection was performed at baseline, 48 and 96 h followed by sacrifice of the mouse, in order to maximise the observed level of renal damage following contrast administration. Serum creatinine however, is relatively insensitive only rising out of the normal range when 50% of the functioning renal mass is lost . Furthermore even modest changes in serum creatinine have a strong association with in-hospital mortality . Subclinical markers of kidney injury, such as, NGAL, retinol binding protein and albumin/creatinine ratios, not only allow the identification of renal damage that is not normally identified by creatinine measurement alone, but also they can potentially can identify the beneficial impact of therapies aimed at mitigating the effects of radio-contrast media. Furthermore, the evaluation of peri-operative renal function and the impact of therapeutic strategies have been hampered by the lack of sensitive and specific biomarkers of acute kidney injury. We have previously shown the value of retinol binding protein (RBP) as a reliable biomarker of CIN [8, 22]. In more contemporary work we have also demonstrated the potential of NGAL to identify early renal injury in patients undergoing endovascular AAA repair . In this study, the positive control data from the murine model confirmed observations in previous studies [17, 24, 25] where it was demonstrated that apoptosis triggered by CIN resulted in a higher frequency of apoptotic cells in the glomerulus and renal tubules. This supports the notion that at least one potential mechanism of CIN in patients may involve caspase-dependent apoptosis, moreover administration of high dose AA appears to reduce apoptosis in the glomerulus.. There also appears to be a dose-response relationship with regard the effect of AA administration on apoptosis. One unexpected finding was the fact that the low dose AA appeared to have a more potent effect in reducing NGAL expression (as both NGAL protein and Lcn-2 transcript) in the kidneys. There is no clear explanation for this result although differences in the dose groups may be due to the kinetics of NGAL induction (which were not investigated in this study), thus the timing of the kidney removal after treatment with contrast media may explain this finding. It is clear that these preliminary observations offer potential insights into the mechanisms of CIN and possible treatments to ameliorate nephrotoxicity although further work is required in both animal models and patients to understand optimal dosing of AA and to investigate the effects of AA in reducing oxidative stress in kidneys. One of the limitation of this study is that biomarkers of oxidative stress were not measured and this may have thrown further light on the mechanism of action of ascorbic acid in reducing CIN.
The concerns regarding CIN in EVAR patients are not just related to the index procedure. There is increasing evidence of long-term renal dysfunction that maybe related in part to further contrast administration during surveillance CT imaging or at the time of subsequent reinterventions. Measures to ameliorate CIN should be taken during any subsequent contrast administration in higher risk EVAR patients. There is now good contemporary data confirming that AA reduces the incidence of CIN in patients undergoing coronary angiography by up to a third . One would anticipate that a similar benefit would be observed in patients undergoing peripheral vascular and aortic interventions. High dose AA appears to be well tolerated in the coronary population and the data presented in this study would support a clinical trial of AA in patients undergoing non-coronary endovascular interventions.
In conclusion this study presents comprehensive basic science evidence for the role of AA as a nephroprotective agent following contrast administration. Further work is warranted to establish the role of this therapy in the prevention of CIN in humans undergoing endovascular procedures.
Availability of data and materials
All ELISA, qRT-PCR and urinary analysis raw data is provided as supplementary data.
KR performed molecular biology and NGAL ELISA; AN performed urine analysis; LJ performed qRT-PCR; MG performed histology; TJ setup mouse studies; MB and JB conceived and coordinated the study. All authors read and approved the final manuscript.
The authors declare that they have no competing interest.
Consent for publication
Charles River UK is Designated Breeding and Research Establishment under the Animal (Scientific Procedures) Act 1986 (revised 2013). As required under the Act, the Charles River UK has an active Animal Welfare and Ethical Review Body (AWERB) in place to advise the Establishment Licence holder on all animal matters, to ensure that the regulated activities carried out at the Establishment are carried out in a manner that is consistent with the principles of replacement, reduction and refinement (the 3Rs). All research performed at the Charles River site is completed under approved Project Licences detailing the harm-benefit justification for the use of animals and the application of the 3R’s. All Project protocols are reviewed and approved by the Project Licence Holder, the local AWERB, the Establishment Licence Holder, and finally by the UK Secretary of State.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Walsh SR, Tang TY, Boyle JR. Renal consequences of endovascular abdominal aortic aneurysm repair. J Endovasc Ther. 2008;15:73–82.View ArticlePubMedGoogle Scholar
- Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. Am J Kidney Dis. 2002;39:930–6.View ArticlePubMedGoogle Scholar
- Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation. 2002;105:2259–64.View ArticlePubMedGoogle Scholar
- McCullough PA, Wolyn R, Rocher LL, Levin RN, O’Neill WW. Acute renal failure after coronary intervention: Incidence, risk factors, and relationship to mortality. Am J Med. 1997;103:368–75.View ArticlePubMedGoogle Scholar
- Matsumura J, Brewster D, Makaroun M. A multicentre controlled clinical trial of open versus endovascular treatment of abdominal aortic aneurysm. J Vasc Surg. 2003;37:262–71.View ArticlePubMedGoogle Scholar
- Johnston K. Multicentre prospective study of non-ruptured abdominal aortic aneurysm. Part II. Variable predicting morbidity and mortality. J Vasc Surg. 1989;9:437–47.View ArticlePubMedGoogle Scholar
- Kelly A, Dwamena B, Cronin P, Bernstein S, Carlos R. Meta-analysis: Effectiveness of drugs for preventing contrast-induced nephropathy. Ann Intern Med. 2008;148(4):284–94.View ArticlePubMedGoogle Scholar
- Moore N, Lapsley M, Norden A, Firth J, Gaunt M, Varty K, Boyle J. Does N-acetylcysteine prevent contrast-induced nephropathy during endovascular AAA repair? A randomised controlled pilot study. J Endovasc Ther. 2006;13:660–6.View ArticlePubMedGoogle Scholar
- O’Sullivan S, Healy DA, Moloney MC, Grace PA, Walsh SR. The role of N-acetylcysteine in the prevention of contrast-induced nephropathy in patients undergoing peripheral angiography: A structured review and meta-analysis. Angiology. 2013;64(8):576–82. doi:10.1177/0003319712467223. Review. PMID:23188834.
- Spargias K, Alexopoulos A, Kyrzopoulos S, Iacovis P, Greenwood D, Manginas A, Voudris V, Pavlides G, Buller C, Kremastinos D, Cokkinos D. Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation. 2004;110:2837–42.View ArticlePubMedGoogle Scholar
- Tepel M, Van Der Giet M, Schwarzfeld C. Prevention of radiographic contrast-induced-agent-induced reductions in renal function by acetylcysteine. N Engl J Med. 2000;343:180–4.View ArticlePubMedGoogle Scholar
- Zhou L, Chen H. Prevention of contrast-induced nephropathy with ascorbic acid. Int Med. 2012;51(6):531–5.View ArticleGoogle Scholar
- Boscheri A, Weinbrenner C, Botzek B, Revnen K, Kublisch E, Strasser RH. Failure of ascorbic acid to prevent contrast-media induced nephropathy in patients with renal dysfunction. Clin Nephrol. 2007;68(5):279–86.View ArticlePubMedGoogle Scholar
- Brezis M, Rosen S. Hypoxia of the renal medulla—its implications for disease. N Engl J Med. 1995;332:647–55.View ArticlePubMedGoogle Scholar
- Katholi RE, Woods Jr WT, Taylor GJ, Deitrick CL, Womack KA, Katholi CR, McCann WP. Oxygen free radicals and contrast nephropathy. Am J Kidney Dis. 1998;32:64–71.View ArticlePubMedGoogle Scholar
- Tee H, Jan M, Bae S. A1 adenosine receptor knockout mice are protected against acute radiocontrast nephropathy in vivo. Am J Physiol Renal. 2006;290(6):1367–75.View ArticleGoogle Scholar
- Quintavalle C, Brenca M, De Micco F, Fiore D, Romano S, Romano MF, Apone F, Bianco A, Zabatta MA, Troncone G, Briguori C, Condorelli G. In vivo and in vitro assessment of pathways involved in contrast media-induced renal cell apoptosis. Cell Death Dis. 2011;2:e155.View ArticlePubMedPubMed CentralGoogle Scholar
- Norden AG, Lapsley M, Unwin RJ. Urine retinol-binding protein 4: a functional biomarker of the proximal renal tubule. Adv Clin Chem. 2014;63:85–122.View ArticlePubMedGoogle Scholar
- Sadat U, Usman A, Boyle JR, Hayes PD, Solomon RJ. Contrast Medium-Induced Acute Kidney Injury. Cardiorenal Med. 2015;5(3):219–28.View ArticlePubMedPubMed CentralGoogle Scholar
- Ambler GK, Coughlin PA, Hayes PD, Varty K, Gohel MS. Boyle JR Incidence and Outcomes of Severe Renal Impairment Following Ruptured Abdominal Aortic Aneurysm Repair. Eur J Vasc Endovasc Surg. 2015;50(4):443–9.View ArticlePubMedGoogle Scholar
- Weisbord SD, Kip KE, Saul MI, Palevsky PM. Defining clinically significant radiocontrast nephropathy. J Am Soc Nephrol. 2003;14:280A–1A.Google Scholar
- Sadat U, Walsh SR, Norden AG, Gillard JH, Boyle JR. Does oral N-acetylcysteine reduce contrast induced renal injury in patients with peripheral arterial disease undergoing peripheral angiography? A randomized-controlled study. Angiology. 2011;62:225–30.View ArticlePubMedGoogle Scholar
- Noorani A, Sadat U, Chowdhury MM, Rollins KE, Harrison SC, Usman A, Burling K, Nordon AG, Boyle JR. Use of urinary biomarkers for assessment of renal injury in patients undergoing EVAR. Angiology. 2016. [Epub ahead of print].Google Scholar
- Tumlin J, Stacul F, Adam A, Becker CR, Davidson C, Lameire N, McCullough PA. CIN Consensus Working Panel. Pathophysiology of contrast-induced nephropathy. Am J Cardiol. 2006;98(6):14–20.View ArticleGoogle Scholar
- Seeliger E, Sendeski M, Rihal CS, Persson PB. Contrast-induced kidney injury: mechanisms. Risk factors, and prevention. Eur Heart J. 2012;33(16):2007–15.View ArticlePubMedGoogle Scholar
- Sadat U, Usman A, Gillard JH, Boyle JR. Does ascorbic acid protect against contrast-induced acute kidney injury in patients undergoing coronary angiography: a systematic review with meta-analysis of randomized, controlled trials. J Am Coll Cardiol. 2013;62(23):2167–75.View ArticlePubMedGoogle Scholar